Hybridomas and monoclonal antibodies that inhibit...

C - Chemistry – Metallurgy – 07 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C07K 16/28 (2006.01) A61K 39/395 (2006.01) C07K 14/725 (2006.01) C12N 5/20 (2006.01) A61K 38/00 (2006.01)

Patent

CA 2059824

-30- ABSTRACT OF THE DISCLOSURE The present invention relates to antibodies that are immunologically reactive with a T cell surface antigen, CD44. Specifically, the invention relates to monoclonal antibodies, including mAb 212.3, that are immunologically reactive with CD44 and that are able to inhibit OKT3-induced T cell proliferation. The invention also relates to the therapeutic use of such antibodies, including mAb 212.3, and to hybridoma cell lines that produce such antibodies. The invention also relates to an epitope that is comprised of sequences and/or a conformation of sequences present in the CD44 molecule. This epitope is immunologically reactive to mAb 212.3.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Hybridomas and monoclonal antibodies that inhibit... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Hybridomas and monoclonal antibodies that inhibit..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hybridomas and monoclonal antibodies that inhibit... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1706762

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.